Search results
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Morningstar· 6 days agoBy Ben Glickman Kura Oncology said Monday it received a breakthrough therapy designation from regulators for ziftomenib, its potential treatment for a form of leukemia. The San Diego-based biopharmaceutical company said the U.S. Food and
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Market Watch· 6 days agoThe San Diego-based biopharmaceutical company said the U.S. Food and Drug Administration had granted ziftomenib the status as a potential treatment for relapsed/refractory NPM1-mutant acute ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for...
WKRN Nashville· 4 days agoCSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the ...
Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug
Medscape· 5 days agoThe factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal...
CPR Cell Phone Repair Expands in California with New Store in Temecula
Digital Journal· 4 days ago(KSBI) Announces First Quarter 2023 Financial Results and Cash Dividend Laxxon Medical to Participate in the World Orphan Drug Congress USA 2024 HHG Capital ...
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
WKRN Nashville· 4 days agoJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) ...
KKR, Impilo to become equal owners in Immedica Pharma | PE Hub
PE HUB· 5 days agoKKR has agreed to buy into Immedica Pharma, a pharmaceutical company focused on the...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Morningstar· 5 days agoRilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 6 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its ...
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1...
Morningstar· 4 days agoPAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial (NCT06299839) in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation ...